MCOLN3 and mucolipidosis type IV: However, a potential therapeutic implication of the ability of TRPML3 to substitute for TRPML1 is that ectopic expression of the endogenous Trpml3 gene of MLIV patients, provided the technology were developed, could prevent their symptoms.